SIBN Stock Analysis: Buy, Sell, or Hold?
SIBN - SI-BONE, Inc. Common Stock
$19.96
0.48 (2.46%)
▲
5d:
+5.44%
30d:
+21.19%
90d:
+34.77%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When SIBN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SIBN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SIBN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SIBN is currently trading at $19.96, which is considered extended relative to its 30-day fair value range of $17.17 to $19.07.
Technical Outlook: Technically, SIBN is in a strong uptrend. The price is approaching resistance at $20.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SIBN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+28.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SIBN is in a strong uptrend. The price is approaching resistance at $20.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SIBN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+28.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.17 -
$19.07
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.3% below Wall St target ($25.00)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$17.17 -
$19.07
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$18.39
Resistance Level
$20.05
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-58.89
Wall Street Target
$25.00
(+28.3%)
Revenue Growth (YoY)
15.2%
Profit Margin
-6.9%
Share & Embed Analysis
Last updated: August 23, 2026 12:28 AM ET
Data refreshes hourly during market hours. Next update: 1:28 AM
Data refreshes hourly during market hours. Next update: 1:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SIBN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Anshul Maheshwari
SELL
3318 shares
2026-04-02
Michael A Pisetsky
SELL
1335 shares
2026-04-02
Michael A Pisetsky
SELL
1799 shares
2026-04-01
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 37 SELL |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 49 HOLD |
